September 23-25, Switzerland

Free Registration, Part of MipTec 2014, Congress Center Basel

FREE DRUG DISCOVERY CONFERENCE IN THE HEART OF EUROPE

MipTec is the largest drug discovery conference in Europe with over 3,000 delegates from pharmaceutical companies

ATTEND 10 OTHER SCIENTIFIC FORUMS AT MIPTEC

Stem Sells, Translational Medicine, Protein Therapeutics, Medicinal Chemistry and others

IN SILICO APPROACHES TO GEROPROTECTOR DISCOVERY AND DRUG REPURPOSING

New in silico approaches to evaluating the efficacy of and repurposing drugs for aging and age-related diseases

MEET YOUNG PROSPECTIVE SCIENTISTS AND RESEARCH MANAGERS

The forum will attract many young scientists in aging research providing the possibility to recruit scarse talent with unique skills and interests

AGING CONFERENCE FOCUSED ON REINVENTINT THE PHARMA INDUSTRY

Unlike other aging conferences, the forum is geared towards the pharmaceutical industry addressing the need for new markers and new drugs within the traditional regulatory frameworks

Tuesday, August 26, 2014

Effects of mTOR Inhibition on Immunosenescence in Elderly Humans: Dr. Glass of Novartis Institutes for Biomedical Research to present @ the Aging Forum in Basel

It looks like Dr. Brian Kennedy and Dr. Mikhail Blagosklonny will find themselves in great company.



Presentation Title: Effects of mTOR Inhibition on Immunosenescence  in Elderly Humans
Abstract: Inhibition of the mTOR pathway extends lifespan in all species studied to date, and in mice delays the onset of aging-related diseases and co-morbidities.  However, it is unknown if mTOR inhibition impacts aging in humans.  To begin to assess the effects of mTOR inhibition on human aging-related phenotypes, we evaluated whether the mTOR inhibitor RAD001 ameliorates immunosenescence (the decline in immune function during aging) in elderly volunteers, as assessed by response to influenza vaccination.  Our findings suggest that RAD001 enhanced the response to influenza vaccine in elderly volunteers at doses that were well tolerated. These results suggest that mTOR inhibition has beneficial effects on immunosenescence in elderly volunteers. It remains to be determined if mTOR inhibitors improve other aging-related conditions in humans.

Authors: J. Mannick1*,  G. Del Giudice2, M. Lattanzi2, N. Valiante2, J. Praestgaard1, B. Huang1, M. Lonetto1, H. Maecker3, J. Kovarik1, S. Carson4, D. Glass1, L.  Klickstein1
Affiliations: 1Novartis Institutes for Biomedical Research, Cambridge, MA, USA.
2Novartis Vaccines and Diagnostics, Siena, Italy, and Cambridge, MA, USA.
3Stanford University School of Medicine, Stanford, CA, USA
4 Southern Clinical Trials, Christchurch, New Zealand

Sunday, August 3, 2014

Program Update: New Speakers from Harvard, Rosewell Park and other institutions


The science program of the conference is updated with the new speakers from Harvard, Rosewell Park and other institutions. Please register at the conference website to reserve your seat.
http://www.miptec.ch/miptec2014/organize-your-attendance/registration-information.html

Please download the conference program here:
http://www.slideshare.net/biogerontology/aging-pharma-zhavoronkov030914


International Symposium on Geroprotectors: Practical applications of aging research for drug discovery
23.09, Tuesday: Keynotes/General



08.00 - 08.30
Advances in aging biomarkers and drugs with geroprotective properties
Brian Kennedy
Director, CEO
Buck Institute for Aging Research
08.30 - 09.00
New approaches in aging diagnostics and interventions
Charles Cantor
    Professor
Boston University
09.00 - 9.30
TBD
Nir Barzilai
Director
Albert Einstein College of Medicine
9.30-10.30
ROUND TABLE (Bhupinder Bullar to organize): how can large pharma engage in aging research?
Session I: Predicting the activity of geroprotective drugs: in-silico screening, omics data analysis and rational drug design; Session Chair: Joao Pedro Megalhaes, PhD
10.30 - 11.00
Novel methods for selecting targeted drugs for personalized medicine in oncology
Anton Buzdin
President, CEO
Pathway Pharmaceuticals
11.00 - 11.30
Bioinformatic analysis of the “omics” data from long-lived animals for geroprotector discovery
Joao Pedro De Magalhaes
Lab Head
University of Liverpool
11.30 - 12.00
In silico screening for novel drugs with geroprotective properties
Alexander Zhavoronkov
Director
The Biogerontology Research Foundation
Lunch




13.30-14.15
TBD
Dr. Jörg Reinhardt
Chairman
Novartis
Session II: Drugs with the potential geroprotective properties
Session Chair: TBD

14.30 - 15.00
Using novel isotopically-fortified organic compounds to slow down the aging processes
and treat age-related diseases
Robert Molinari
CEO
Retrotope, Inc
15.00 - 15.30
Advances in the Advanced Glycation Endproduct (AGE) breakers
William Bains
Head of the SENS Laboratory
Cambridge
15.30 - 16.00
Overview of the possible geroprotectors
Sven Bulterijs
Post-grad researcher
Yale University
16.00 - 16.30
Coffee Break



16.30 - 17.00
Applied Epigenetics of Aging and Longevity
Olga Kovalchuk
Professor, Lab Head
University of Lethbridge
24.09, Wednesday: Keynotes/General



08.00 - 08.30
Rapamycin and other geroprotectors
Mikhail Blagosklonny
Professor, editor-in-chief of Aging
Rosewell Park, NY
08.30 - 09.00
TBD
Blanka Rogina
Director Genetics & Developmental Biology Graduate Program
University of Connecticut
09.00 - 09.30
TBD
James Kirkland
Professor
Mayo Clinic
09.30 - 10.00
How to Solve Genetic Disease on a Population Scale
Barry Merriman
Professor/ Lead System Architect, CSO
UCLA/Thermo Fisher Scientific
10.00 - 10.30
Coffee Break



Session III: Aging Biomarkers: how do we measure aging and geroprotective efficacy
Session Chair: Alexander Bürkle, PhD
10.30 - 11.00
Lessons learned from the EU FP7 MARKAGE Project
Alexander Bürkle
Professor, MARK-AGE Co-ordinator
University of Konstanz
11.00-11.30
Comparative genomics of aging and longevity
Vadim Gladyshev
Professor, Department of Medicine, Harvard Medical School
Director of Redox Medicine, Brigham And Women's Hospital
Harvard
11.00 - 11.30
Gene expression patterns in progeria and age-related diseases
Antonei Benjamin Csoka
Assoc. Professor
Howard University
11.30 - 12.00
Genetic and Epigenetic Biomarkers of Aging
Alexey A Moskalev
Professor, head of the laboratory
Moscow Institute of Physics and Technology
Lunch




13.30-14.15
TBD
Prof. Patrick Aebischer
President
Ecole Polytechnique Fédérale de Lausanne (EPFL)
Session IV: Trends in Aging Research for Drug Discovery
Session Chair: Richard Faragher, PhD
14.30 - 15.00
Ageing Research and Regenerative Medicine Industry Outlook
Charles Groome and Geoffrey Furlonger
Head of Communications
Aging Analytics
15.00 - 15.30
Industry Partnerships for Ageing Research
David Brindley
Research Fellow in Cell Therapy Commercialization / Researcher
Harvard Stem Cell Institute / University of Oxford, NDORMS
15.30 - 16.00
Big Data in Biomedicine: Applying machine learning to predict the outcomes of biomedical research projects
Dmitry Kaminskiy
Director, Senior Partner
Deep Knowledge Ventures
16.00 - 16.30
Coffee Break



16.30 - 17.00
TBD
Richard Faragher
Professor
University of Brighton
Backup keynote speaker (23 or 24)



TBD
New drug discovery: AK-1 for radioprotection, AK-2 for antiviral and AK-3 for anti-aging
Grace Wong
CEO
Actokine